GRT Capital Partners L.L.C. held its stake in shares of Abbott Laboratories (NYSE:ABT) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,130 shares of the healthcare product maker’s stock at the close of the 2nd quarter. GRT Capital Partners L.L.C.’s holdings in Abbott Laboratories were worth $492,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. State Street Corp increased its holdings in shares of Abbott Laboratories by 18.9% during the 1st quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after purchasing an additional 12,806,535 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Abbott Laboratories by 7.7% during the 2nd quarter. Alliancebernstein L.P. now owns 11,607,121 shares of the healthcare product maker’s stock valued at $564,222,000 after purchasing an additional 830,610 shares in the last quarter. Boston Partners increased its holdings in Abbott Laboratories by 28.1% in the 2nd quarter. Boston Partners now owns 10,516,502 shares of the healthcare product maker’s stock worth $511,207,000 after acquiring an additional 2,304,467 shares in the last quarter. Independent Franchise Partners LLP increased its holdings in Abbott Laboratories by 0.8% in the 2nd quarter. Independent Franchise Partners LLP now owns 9,828,141 shares of the healthcare product maker’s stock worth $477,745,000 after acquiring an additional 76,935 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Abbott Laboratories by 33.8% in the 1st quarter. Ameriprise Financial Inc. now owns 8,823,399 shares of the healthcare product maker’s stock worth $391,841,000 after acquiring an additional 2,231,316 shares in the last quarter. Institutional investors and hedge funds own 71.01% of the company’s stock.
Shares of Abbott Laboratories (ABT) opened at $54.79 on Wednesday. Abbott Laboratories has a 1-year low of $37.42 and a 1-year high of $56.69. The stock has a market cap of $95,228.27, a price-to-earnings ratio of 22.70, a PEG ratio of 2.05 and a beta of 1.06. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were issued a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.93%. The ex-dividend date of this dividend was Thursday, October 12th. Abbott Laboratories’s payout ratio is 83.47%.
Several brokerages recently commented on ABT. ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price target for the company in a report on Tuesday, October 31st. Barclays reissued an “overweight” rating on shares of Abbott Laboratories in a report on Thursday, October 19th. Citigroup reissued a “neutral” rating on shares of Abbott Laboratories in a report on Thursday, October 19th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Abbott Laboratories in a report on Thursday, October 19th. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $56.81.
In other news, insider Sharon J. Bracken sold 2,188 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $56.12, for a total transaction of $122,790.56. Following the completion of the sale, the insider now owns 25,618 shares of the company’s stock, valued at $1,437,682.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jaime Contreras sold 52,700 shares of the business’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the transaction, the insider now directly owns 58,739 shares in the company, valued at approximately $3,052,665.83. The disclosure for this sale can be found here. Insiders have sold 311,127 shares of company stock valued at $16,958,579 in the last ninety days. Insiders own 0.76% of the company’s stock.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
What are top analysts saying about Abbott Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abbott Laboratories and related companies.